Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.41 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.41 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259653 | 0.92 | MAPT (0.44) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL9778713 | 0.82 | CA12 (0.56) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL9636565 | 0.82 | SMN1; SMN2 (0.53) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL28373802 | 0.80 | SLC18A3 (0.45) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL28368682 | 0.80 | SLC18A3 (0.45) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL28368681 | 0.80 | SLC18A3 (0.45) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL4169410 | 0.78 | ALDH1A1 (0.58) | ALDH1A1ACHEMAPTHTTKMT2A | |
| SCHEMBL1583098 | 0.78 | TSHR (0.46) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL1582559 | 0.78 | TSHR (0.46) | EPHX1ALDH1A1ACHEHSD17B10MAPT | |
| SCHEMBL8976434 | 0.78 | ALDH1A1 (0.45) | EPHX1ALDH1A1ACHEHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515623-B | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2025-04-25 | — | — | CN | claimed |
| CN-118459418-B | Hydroxamic acid HDAC inhibitor and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2025-04-08 | — | — | CN | claimed |
| CN-118515623-A | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2024-08-20 | — | — | CN | claimed |
| CN-118459418-A | Hydroxamic acid HDAC inhibitor and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2024-08-09 | — | — | CN | claimed |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-15 | — | — | US | disclosed |
| CN-118515623-B | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-118459418-B | Hydroxamic acid HDAC inhibitor and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-114746434-B | Antibiotic compounds | 莱顿大学 | 2025-02-21 | — | — | CN | disclosed |
| CN-119137106-A | Arylbenzisoxazole compounds as IP6K and IPMK inhibitors and methods of use thereof | 北卡罗来纳查佩尔山大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-4472954-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4034547-B9 | ANTIBIOTIC COMPOUNDS | UNIV LEIDEN (NL) | 2024-09-04 | — | — | EP | disclosed |
| CN-118515623-A | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2024-08-20 | — | — | CN | disclosed |
| WO-2002024687-A1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| EP-0630261-A4 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS. | AUSTRALIAN COMMERCIAL RESEARCH (AU) | 1996-11-06 | — | — | EP | disclosed |
| EP-0630261-A1 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993017711-A1 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1993-09-16 | — | — | WO | disclosed |
| US-4977272-A | Radiation absorbers | THE STANDARD OIL COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| US-4868061-A | ADDITION POLYMERS, ULTRAVIOLET RADIATION STABILIZERS | THE STANDARD OIL COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4740611-A | N,N'-disubstituted ureas | THE STANDARD OIL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4705864-A | Aryl oxime derivatives of hydantoins | THE STANDARD OIL COMPANY (US) | 1987-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | PFKL, IP6K2, IP6K1 | EPHX1 1569/4885ALDH1A1 851/4885ACHE 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.